Artiva Biotherapeutics (NASDAQ:ARTV) COO Sells $57,250.80 in Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) COO Jennifer Bush sold 8,370 shares of the company’s stock in a transaction dated Monday, October 5th. The stock was sold at an average price of $6.84, for a total value of $57,250.80. Following the completion of the sale, the chief operating officer directly owned 366,159 shares of the company’s stock, valued at $2,504,527.56. The trade was a 2.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Artiva Biotherapeutics Stock Performance

ARTV stock opened at $6.80 on Friday. The firm has a market cap of $332.45 million, a P/E ratio of -2.06 and a beta of 2.40. Artiva Biotherapeutics, Inc. has a 1 year low of $2.71 and a 1 year high of $14.53. The stock has a 50-day simple moving average of $9.89 and a 200-day simple moving average of $9.25.

Artiva Biotherapeutics (NASDAQ:ARTV) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.63) EPS for the quarter, hitting the consensus estimate of ($0.63). On average, equities research analysts predict that Artiva Biotherapeutics, Inc. will post -2.62 EPS for the current year.

Institutional Trading of Artiva Biotherapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in ARTV. BlackRock Inc. acquired a new position in Artiva Biotherapeutics during the 2nd quarter valued at approximately $6,739,000. ADAR1 Capital Management LLC acquired a new stake in Artiva Biotherapeutics in the second quarter worth $1,151,000. Nantahala Capital Management LLC bought a new stake in Artiva Biotherapeutics in the second quarter valued at $2,910,000. Alyeska Investment Group L.P. lifted its stake in Artiva Biotherapeutics by 173.6% in the second quarter. Alyeska Investment Group L.P. now owns 273,615 shares of the company’s stock valued at $2,654,000 after buying an additional 173,615 shares during the last quarter. Finally, Blue Owl Capital Holdings LP acquired a new position in shares of Artiva Biotherapeutics during the second quarter valued at $8,483,000.

Analyst Upgrades and Downgrades

ARTV has been the subject of several recent analyst reports. Cantor Fitzgerald restated an “overweight” rating and set a $40.00 target price on shares of Artiva Biotherapeutics in a research note on Friday, October 2nd. Wall Street Zen upgraded Artiva Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. HC Wainwright reissued a “buy” rating on shares of Artiva Biotherapeutics in a report on Friday, October 2nd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Tuesday, July 21st. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Artiva Biotherapeutics currently has an average rating of “Moderate Buy” and an average target price of $39.00.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc (NASDAQ:ARTV) is a clinical-stage biotechnology company developing allogeneic natural killer (NK) cell therapies for cancer and autoimmune diseases. The company’s approach is designed to produce off-the-shelf cell therapies that can be manufactured at scale and administered without using cells collected from each individual patient.

Artiva’s lead investigational product, AlloNK, also known as AB-101, is an allogeneic NK cell therapy being evaluated in combination with rituximab for autoimmune conditions, including systemic lupus erythematosus and lupus nephritis.